A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP-Reference-Cited by-同舟云学术

A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP

Published:2015-03-05 Issue:10 Volume:125 Page:1541-1547
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhou Hai¹,Xu Miao¹,Qin Ping¹,Zhang Hai-yan²,Yuan Cheng-lu³,Zhao Hong-guo⁴,Cui Zhong-guang⁴,Meng Yue-sheng⁵,Wang Lei⁵,Zhou Fang⁶,Wang Xin⁷,Li Da-qi⁸,Bi Ke-hong⁹,Zhu Chuan-sheng⁹,Guo Cheng-shan¹⁰,Chu Xiao-xia¹¹,Wu Qing-chao¹²,Liu Xin-guang¹,Dong Xiao-yuan¹,Li Jie¹,Peng Jun¹¹³,Hou Ming¹¹³

Affiliation:

1. Department of Hematology, Qilu Hospital, Shandong University, Jinan, China;

2. Department of Hematology, Linyi People's Hospital, Linyi, China;

3. Department of Hematology, Qingdao Central Hospital, Qingdao, China;

4. Department of Hematology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, China;

5. Department of Hematology, Qingdao Municipal Hospital, Qingdao, China;

6. Department of Hematology, The General Hospital of Jinan Military Commanding Region, Jinan, China;

7. Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, China;

8. Department of Hematology, Shandong University Affiliated Jinan Center Hospital, Jinan, China;

9. Department of Hematology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China;

10. Department of Hematology, Second Hospital of Shandong University, Jinan, China;

11. Department of Hematology, Yantai Yuhuangding Hospital, Yantai, China;

12. Department of Hematology, Qingdao Haici Hospital, Qingdao, China; and

13. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, China

Abstract

Key Points Rituximab plus recombinant human thrombopoietin is superior to rituximab monotherapy for corticosteroid-resistant or relapsed ITP patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/10/1541/1382954/1541.pdf

Reference48 articles.

1. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment.;Berchtold;Blood,1993

2. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.;Olsson;Nat Med,2003

3. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.;McMillan;Blood,2004

4. The ITP syndrome: pathogenic and clinical diversity.;Cines;Blood,2009

5. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.;Rodeghiero;Blood,2009

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant human thrombopoietin improves platelet engraftment after autologous hematopoietic stem cell transplantation in patients with aggressive lymphoma;Transfusion and Apheresis Science;2024-10

2. Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China;Intractable & Rare Diseases Research;2024-08-31

3. Refractory immune thrombocytopenia responding to combination therapy of eltrombopag and low-dose rituximab: a case series;Hematology, Transfusion and Cell Therapy;2024-08

4. Efficacy of thrombopoietin receptor agonists versus rituximab in non‐responsive immune thrombocytopenia—A single centre retrospective analysis;British Journal of Haematology;2024-07-07

5. Rituximab as a treatment for refractory immune thrombocytopenia during pregnancy;Blood Coagulation & Fibrinolysis;2024-05-22